

13th February, 2018

To

The Manager,

Department of Corporate Services,

BSE Limited,

Phirozejeebhoy Towers,

Dalal Street, Fort, Mumbai-400001.

Dear Sir,

Sub : Outcome of Board Meeting held on 13th February, 2018— unaudited financial results for the quarter ended December 31, 2017

Ref. Scrip Code : 531625, ISIN: INE431E01011

With reference to the cited subject and further to our letter dated 6th February, 2018, we would like to inform you that the Board of Directors, at their meeting, held on 13th February, 2018 at 4.00 P.M. at the registered office of the Company, has inter-alia, considered and approved the un-Audited financial results for the quarter ended on December 31, 2017.


Pursuant to the provision of Regulation 30(6) and Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015; we hereby enclose a copy of the un-Audited financial results for the quarter ended on December 31, 2017 along with the Limited Review Report obtained from our Statutory Auditors.

We request you to take the above information on record.

Thanking you,

Yours Truly,

For Sangam Health Care Products Limited


(BALA GOPAL ADDEPALLI)

Managing Director

(DIN: 01712903)

Encl. As above



LIMITED REVIEW REPORT

The Board of Directors.

Sangam Health Care Products limited

We have reviewed the accompanying statement of unaudited financial results of Sangam Health Care Product Limited, Secunderabad for the quarter and six months ended 31st December, 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410. "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express any audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2004 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.R. Shekher & Co.,
Chartered Accountants
FRN : 010828S

Rajashekhar Kaparti
Partner

Membership No. 214810

Place: Hyderabad
Date: 07 -02-2018

SANGAM HEALTH CARE PRODUCTS LIMITED							
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DEC 31, 2017							
SI No.	Particular	Quarter ended			Nine Months ended		Year Ended
		31.12.2017 [Un-audited]	30.09.2017 [Un-audited]	31.12.2016 [Un-audited]	31.12.2017 [Un-audited]	31.12.2016 [Un-audited]	31-03-2017 [Audited]
I	Revenue from operations	656.06	511.16	507.85	1610.46	1898.06	2361.69
II	b) Other operating income	0.499	-	0	0.499	0.9	12
III	TOTAL (I + II)	656.56	511.16	507.85	1610.96	1898.96	2373.69
IV	Expenses:						
	Cost of material consumed	393.38	227.02	286.75	833.19	845.29	1095.66
	Purchase of Stock-in-trade	-	-	-	-	-	-
	Changes in inventories of Finished goods, work-in-progress & Stock in trade	-71.34	70.27	-67.64	-39.95	-22.54	201.31
	Employees benefit expenses	124.68	109.34	144.8	345.91	385.18	524.54
	Finance Cost	101.35	107.99	100.33	320.2	316.89	504.86
	Depreciation & amortization expenses	37.85	38.14	38.14	114.13	114.42	152.17
	Other expenses	93.49	102.53	117.45	306.26	445.67	579.15
	Total Expenses	679.41	655.29	619.83	1879.74	2084.91	3057.69
V	Profit before tax (3 - 4)	-22.85	-144.13	-111.98	-268.78	-185.95	-684
VI	Tax expense:						
	(1) Current tax	-	-	-	-	-	-
	(2) Deferred tax	-	-	-	-	-	1.66
VII	Profit (Loss) for the period from continuing operations (7 - 8)	-22.85	-144.13	-111.98	-268.78	-185.95	-685.66
VIII	OTHER COMPREHENSIVE INCOME						
	A- (i) Items that will be reclassified to the profit or loss or loss	-	-	-	-	-	-
	B- (I) Items that will not be reclassified to the profit or loss	-22.85	-144.13	-111.98	-268.78	-185.95	-685.66
	a) Remeasurement of defined employee benefit plans						
	(ii) Income tax on items that will not be reclassified to the profit						
	Total Other comprehensive Income (net of taxes)						
	Total Comprehensive Income for the Period						
IX	Earnings per Equity share-Basic and diluted (Not annualised)	-22.85	-0.096	-0.07	-1.81	-1.25	-0.46
	Weighted average number of equity share (in No's Lakhs)						

Abhah

Nature of Adjustments	Note No	For te Quarter	For te year
		ended 31.12.2017	ended
As per the Previous GAAP		-22.85	-268.78
As per Ind AS		-22.85	-268.78

Note

1. The Limited Review of the Financials has been carried out by the Statutory Auditors of the Company in terms of of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. The Company has adopted Indian Accounting Standards ["Ind AS"] effective April 01, 2017 and accordingly, the financial results for the quarter ended Dec 31, 2017 have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 "Interim Financial reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular CIR/CFD/FAC/62/2016 dated July 05, 2016. The results for the comparative quarter ended Dec 31, 2016 have been restated in accordance with Ind AS. After adoption of Ind AS the financial results for the quarter ended Dec 31 2016 have not been audited or reviewed by the auditors and are compiled by the management after exercising necessary due diligence to ensure that these give a true and fair view of the company's affairs.
3. The Segment reporting as defined in Accounting Standiand-17 is not applicable, as the operation of the Company are related to one Segment
4. Previous Accounting period's figures have been grouped/regrouped wherever considered necessary.

For Sangam Health Care Products Limited

A Bala Gopal

Chairman and Managing Director

DIN: 01712903

Place: Hyderabad

Date: February 13, 2018

SANGAM HEALTHCARE PRODUCTS LTD
Provisiona Statement of Assts and Liabilites

(amt in lakhs)

Particulars	As at 31.12.17 Un audited
Assets	
1) Non-Current Assets	
a) Property, Plant and Equipment	2,030
b) Capital Work in Progress	
c) Intangible assets	-
d) Other financial assets	123
Sub- Non- Current Assets	2,154
2. Current Assets	
a) Inventories	510
b) Fiancial Assets	
(i) Investments	-
(ii) Trade receivables	59
(iii) Cash and Cash equivalents	28
(iv) Others financial assets	-
c) other current assets	
Sub- Current Assets	597
Total Assets	2,751

A. B. Balakrishna


EQUITY AND LIABILITIES	
Equity	
a) Share Capital	1,486
b) Reserve and Surplus	-4,290
	-2,804
Liabilities	
Non-Current Liabilities	
a) Financial Liabilities	
(i) Borrowings	3,402
b) Deffered Tax Liabilities	78
	3,479
Current Liabilities	
(a) Financial Liabilities	
(i) Borrowings	944
(ii) Trade Payables	408
b) Other Current Liabilities	724
c) Current tax liabilities	
d) Provisions	
	2,075
Total Equity and liabilities	2751

For Sangam Health Care Products Limited

A. Balagopal

Chairman and Managing Director

DIN: 01712903

Place: Hyderabad

Date: February 13, 2018

